Anthem Biosciences LimitedQ1 FY27 Results & Financial Update
Anthem Biosciences Limited: Q1 FY27 consolidated results and company financials – revenue ₹418.22 Cr, PAT ₹119.94 Cr. Explore reported YoY/QoQ movements, margins, business drivers and management commentary. This page does not provide a rating, target price or investment recommendation.
Quarter at a glanceCurrent reported figures.Change figures appear when a comparable reported period is available.
Find an answer
Ask this result
Chart · Market context
Anthem Biosciences price & chart
Market price₹822.15
1Y return—Price return
Loading market chart…
TradingView Lightweight Charts™ · Copyright © 2025 TradingView, Inc.TradingView
Market chartPrice chart temporarily unavailableThe price chart could not be loaded right now. The reported financial results remain available above.
Spotted a factual error?Tell us the number, date or statement and we will re-check the underlying records and calculations.Report an error
Quarterly Results AnalysisExplore Anthem Biosciences Q1 FY27 quarterly results and earnings: revenue, profit (PAT), EBITDA, margins, YoY and QoQ growth, order book or business updates where reported, financial performance and management commentary. Reported figures and Nivata calculations are shown separately; no buy, sell or hold recommendation is provided.
Quarter overview
Quarterly earnings analysis
Anthem Biosciences reported consolidated revenue from operations of ₹4,182.18 crore (₹4,182 million) for the quarter ended June 30, 2026, marking a decrease compared to ₹5,402.09 crore in the corresponding quarter of the previous year and ₹6,109.43 crore in the preceding fourth quarter of FY26.
Management attributed the top-line contraction during Q1 FY27 to timing shifts in customer deliveries rather than any structural demand erosion. The company noted that underlying demand remains robust, with a higher concentration of scheduled dispatches anticipated in the latter half of the fiscal year.
Consolidated EBITDA for the quarter stood at ₹175.50 crore (₹1,755 million), resulting in an EBITDA margin of 39.6%. This reflects a year-on-year expansion of 153 basis points compared to 38.1% in Q1 FY26, supported by disciplined cost efficiencies, yield optimization, and employee productivity.
The company's balance sheet remained robust with a net cash position of ₹1,719.70 crore (₹17,197 million) as of June 30, 2026, compared to ₹784.80 crore a year ago, underpinning strong financial flexibility and liquidity.
Profit after tax was ₹119.94 Cr for the reported quarter. EPS was ₹2.11 for the reported quarter.
01 · Business model
What does Anthem Biosciences do?
Anthem Biosciences Limited is an innovation-driven and technology-focused Contract Research, Development and Manufacturing Organization (CRDMO) headquartered in Bengaluru, Karnataka. The company provides fully integrated services spanning drug discovery, development, and commercial manufacturing for both small and large molecules globally.
The business operates across specialized segments, featuring integrated capabilities in New Chemical Entities (NCE) and New Biological Entities (NBE). Its operations encompass drug discovery, custom synthesis, late-stage development, and commercial production serving emerging biotech and large pharmaceutical clients worldwide.
Anthem's manufacturing and research infrastructure is anchored across multiple facilities in Karnataka, including Unit I in Bommasandra and Units II and III in Harohalli, alongside specialized operational subsidiaries such as Neoanthem Lifesciences Private Limited.
02 · Historical context
What shaped the business before this quarter
Previously operating as Anthem Biosciences Private Limited, the entity transitioned its corporate status to Anthem Biosciences Limited following equity and regulatory restructuring.
The company established and executed ESOP Scheme 2024, leading to subsequent equity allotments approved by the Board in prior periods.
03 · Financial snapshot
Current-quarter financial snapshot
| Metric | Q1 FY27 |
|---|---|
| Revenue from operations | ₹418.22 Cr |
| Total income | ₹443.11 Cr |
| Profit before tax | ₹144.58 Cr |
| Profit after tax | ₹119.94 Cr |
| EPS | ₹2.11 |
04 · Why it moved
Why the quarter looked the way it did
What drove revenue
The CRDMO business delivered revenue of ₹3,408.02 crore during Q1 FY27, accounting for approximately 81.5% of total operating revenues.
Specialty Ingredients generated revenue of ₹774.16 crore for the quarter, contributing approximately 18.5% to the consolidated top-line mix.
Revenue recognition was impacted by scheduled delivery timelines shifting toward subsequent quarters of FY27, leading to a temporary sequential and annual dip in recognized sales.
What drove margins
EBITDA margin strengthened to 39.6% in Q1 FY27 compared to 38.1% in Q1 FY26, driven by yield optimization and operational cost controls.
Cost of materials consumed and inventory adjustments moderated to ₹146.20 crore (combined inventory and consumption lines), easing raw material pressures.
Employee benefit expenses stood at ₹78.84 crore for the consolidated entity, reflecting productivity enhancements and team scaling.
05 · Demand, customers & order book
Where demand is coming from
Maintains an active portfolio spanning 14 commercial molecules and 10 late-stage (Phase III) development molecules.
06 · Segments, products & geography
Which parts of the business are doing the work
Segments and products
Delivered ₹3,408.02 crore in revenues with a segment gross profit of ₹232.26 crore before unallocated expenditures.
Contributed ₹774.16 crore in revenue with gross segment profit of ₹39.76 crore for the quarter.
Geography and market mix
Serves innovator-focused emerging biotech and large multinational pharmaceutical companies across international markets alongside domestic operations.
07 · Capacity, projects & execution
What is being built, commissioned or delivered
Capacity, production and utilisation
Maintains custom synthesis capacity of 425 KL alongside fermentation capacity of 142 KL across its manufacturing sites.
Projects, capex and execution
Gross fixed assets turnover stood at 1.10x for Q1 FY27, reflecting efficient deployment of capital infrastructure across manufacturing units.
08 · Strategy & new businesses
How the company is trying to change its growth mix
Incorporates operations through wholly owned subsidiary Neoanthem Lifesciences Private Limited to augment specialized life sciences capabilities.
09 · Reported developments
What changed operationally
Achieved year-on-year expansion in both EBITDA margin (39.6% vs 38.1%) and PAT margin (27.1% vs 24.1%) despite lower quarterly revenue recognition.
Net cash reserves more than doubled year-on-year to ₹1,719.70 crore, providing strong financial backing for future operational scale-up.
10 · Pressure points & risks
What is not going smoothly
Consolidated operating revenue decreased by 22.6% YoY to ₹4,182.18 crore due to timing shifts in customer dispatches during the quarter.
11 · Items worth noticing
The line items that can distort a quick read
Quarterly income includes ₹1.30 crore of other operating income from forex gains and RoDTEP incentives, alongside ₹23.60 crore of financial and non-operating income.
12 · Cash flow & balance sheet
Profit is one thing. Cash and funding tell another part of the story.
Net cash reserves expanded substantially to ₹1,719.70 crore as of June 30, 2026, compared to ₹784.80 crore as of June 30, 2025.
Capital allocation & funding
Finance costs remained minimal at ₹0.89 crore (₹8.87 million) for the quarter, reflecting a near debt-free capital structure.
13 · Management guidance & targets
What management is targeting from here
Management stated a firm commitment to sustaining revenue growth aligned with long-term historical performance, backed by a heavier concentration of deliveries scheduled for the second half of FY27.
14 · Beyond the numbers
What changed beyond the numbers
Reported update
Return Ratios
Reported annualized return on equity (ROE) of 15.4% and post-tax ROCE of 23.3% for Q1 FY27.
Reported update
ESOP Allotment
Allotted 1,670,909 fully paid-up equity shares of ₹2 each during the quarter under ESOP Scheme 2024.
15 · Previous-quarter changes
What changed since the previous quarter
Operating revenues and profitability moderated sequentially from Q4 FY26 highs due to normal cyclical delivery scheduling and timing variations.
16 · Key Q&A
The quarter, answered directly
What does Anthem Biosciences do?
Anthem Biosciences Limited is an innovation-driven and technology-focused Contract Research, Development and Manufacturing Organization (CRDMO) headquartered in Bengaluru, Karnataka. The company provides fully integrated services spanning drug discovery, development, and commercial manufacturing for both small and large molecules globally.
What is the clearest takeaway from Q1 FY27?
Anthem Biosciences reported consolidated revenue from operations of ₹4,182.18 crore (₹4,182 million) for the quarter ended June 30, 2026, marking a decrease compared to ₹5,402.09 crore in the corresponding quarter of the previous year and ₹6,109.43 crore in the preceding fourth quarter of FY26.
What drove revenue or demand?
The CRDMO business delivered revenue of ₹3,408.02 crore during Q1 FY27, accounting for approximately 81.5% of total operating revenues.
What mattered most for margins or profitability?
EBITDA margin strengthened to 39.6% in Q1 FY27 compared to 38.1% in Q1 FY26, driven by yield optimization and operational cost controls.
What changed operationally beyond the headline numbers?
Maintains custom synthesis capacity of 425 KL alongside fermentation capacity of 142 KL across its manufacturing sites.
What is management guiding or targeting from here?
Management stated a firm commitment to sustaining revenue growth aligned with long-term historical performance, backed by a heavier concentration of deliveries scheduled for the second half of FY27.
17 · Scenario calculator
Earnings sensitivity: what if growth and margins change?
Starting point
Build your own next-quarter scenario
Reported values are prefilled where a comparable basis is available. Otherwise, the field starts at 0. You can overwrite every field.
Example: enter 10 for 10% revenue growth. Enter -100 for a 1 percentage-point margin decline.
Scenario output
Scenario revenue / income₹0 cr
Scenario profit after tax₹0 cr
Profit change vs base₹0 cr (0%)
Scenario margin0%
Growth needed to keep profit flat after this margin move0%
The calculator holds the selected margin basis constant except for the basis-point adjustment you enter. It does not estimate tax, finance cost, dilution, working capital, valuation or share price.
18 · Next filing checkpoints
What the next disclosure can confirm or change
- 01
H2 Delivery Execution: Monitor execution of scheduled customer deliveries in the second half of FY27 to verify management's guidance on revenue catch-up.
- 02
Margin Sustenance: Track whether EBITDA margins can be sustained near the 39.6% level as delivery volumes scale up across the remainder of the fiscal year.
Learn the metrics
Need the concepts first?
Use Nivata’s plain-English guides to understand the accounting terms used in this brief before interpreting them.